Trial Profile
A phase I open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, immunogenicity and clinical activity of the antibody drug conjugate GSK2857916 in subjects with relapsed/refractory multiple myeloma and other advanced hematologic malignancies expressing BCMA
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Jan 2023
Price :
$35
*
At a glance
- Drugs Belantamab mafodotin (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man; Registrational; Therapeutic Use
- Acronyms DREAMM-1
- Sponsors GlaxoSmithKline; GSK
- 13 Dec 2022 Results exploring whether complete target loss and/or immune impairment were observed in patients who received belamaf in the DREAMM-1 and -2 trials presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 18 Mar 2022 Results assessing to build an integrated time-course model of drug exposure, efficacy, and corneal events for future use in designing clinical studies (DREAMM-1 (NCT02064387) and DREAMM-2 (NCT03525678)), presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 01 Oct 2021 Results assessing efficacy outcomes for Idecabtagene vicleucel versus selinexor plus dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma from phase 2 KarMMa (14 January 2020 data cutoff), STORM part 1 (phase 2) and STORM part 2 (phase 2), DREAMM-1 (phase 1) and DREAMM-2 (phase 2) trials, published in the Leukemia and Lymphoma.